Back to Authors

Zabala Genovez, Jose L

Mayo Clinic

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Citations 1

Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy
Thongprayoon, Charat , Cheungpasitporn, Wisit , Radhakrishnan, Yeshwanter , Genovez, Jose L. Zabala , Shawwa, Khaled , Zabala Genovez, Jose L, Cheungpasitporn, Wisit , Thongprayoon, Charat , Radhakrishnan, Yeshwanter , Petnak, Tananchai , Qureshi, Fawad , Mao, Michael A. , Kashani, Kianoush

Therapeutic Apheresis and Dialysis | January 23, 2022 | Volume: 26 | Issue: 6 | Pages: 1098-1105

10.1111/1744-9987.13804 Get It

AbstractIntroductionWe aimed to assess the association between serum potassium and mortality in patients receiving continuous renal replacement therapy (CRRT).MethodsWe studied 1279 acute kidney injury patients receiving CRRT in a tertiary referral hospital in the United States. We used logistic regression to assess the association of serum potassium before CRRT and mean serum potassium during CRRT with 90‐day mortality after CRRT initiation, using serum potassium 4.0–4.4 mmol/L as reference group.ResultsBefore CRRT, there was a U‐shaped association between serum potassium and 90‐day mortality. There was a significant increase in mortality when serum potassium before CRRT was ≤3.4 and ≥4.5 mmol/L. During CRRT, progressively increased mortality was noted when mean serum potassium was ≥4.5 mmol/L. The odds ratio of 90‐day mortality was significantly higher when mean serum potassium was ≥4.5 mmol/L.ConclusionHypokalemia and hyperkalemia before CRRT and hyperkalemia during CRRT predicts 90‐day mortality.